INVIZIUS
Invizius is developing treatments to help hemodialysis patients live longer, feel better, and suffer fewer cardiovascular complications.
INVIZIUS
Industry:
Biotechnology Health Care Medical
Founded:
2018-01-01
Address:
Edinburgh, Edinburgh, City Of, United Kingdom
Country:
United Kingdom
Website Url:
http://www.invizius.com
Total Employee:
1+
Status:
Active
Total Funding:
10.15 M GBP
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Content Delivery Network Nginx Microsoft Exchange Online Office 365 Mail
Similar Organizations
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
CeQur
CeQur develops and commercializes insulin delivery systems, giving people with type 2 diabetes freedom from multiple daily injections.
xRapid
xRapid is a mobile health diagnosis through disruptive solutions leveraging the use of artificial intelligence.
Current Employees Featured
Founder
Investors List
Biomedical Catalyst Fund
Biomedical Catalyst Fund investment in Grant - Invizius
Jonathan Milner
Jonathan Milner investment in Series A - Invizius
Scottish Enterprise
Scottish Enterprise investment in Series A - Invizius
Mercia Fund Managers
Mercia Fund Managers investment in Series A - Invizius
Old College Capital
Old College Capital investment in Series A - Invizius
Solvay Ventures
Solvay Ventures investment in Series A - Invizius
Downing Ventures
Downing Ventures investment in Series A - Invizius
Calculus Capital
Calculus Capital investment in Series A - Invizius
Old College Capital
Old College Capital investment in Series A - Invizius
Scottish Investment Bank
Scottish Investment Bank investment in Series A - Invizius
Official Site Inspections
http://www.invizius.com
- Host name: 185.60.251.251
- IP address: 185.60.251.251
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Invizius"
About Us - Invizius - second generation complement therapeutics …
Invizius spun out of world-leading research at the University of Edinburgh in 2018 Inspiration > Our team combines world-leading scientists, with senior executives from life science and …See details»
Invizius - LinkedIn
Invizius | 1,028 followers on LinkedIn. Fighting Inflammation at its Source | Invizius is a spin-out based on world-class Complement research carried out at the University of Edinburgh, Scotland.See details»
Invizius - Crunchbase Company Profile & Funding
Invizius offers extra-corporeal treatments for patients that includes dialysis, cardiopulmonary bypass, and ECMO involve the circulation of the patient's blood supply through a machine. …See details»
Invizius - Products, Competitors, Financials, Employees, …
Biotech raises further funds for ‘dialysis breakthrough’ treatment. Sep 24, 2024. Invizius – the Edinburgh-based biotech company developing breakthrough treatments for patients on …See details»
Invizius 2025 Company Profile: Valuation, Funding & Investors
Invizius General Information Description. Operator of a biotech company intended to develop treatments to suppress unwanted innate immune responses. The company's product is an anti …See details»
Invizius Company Profile - Office Locations, Competitors ... - Craft
Invizius has 5 employees across 2 locations and $7.37 m in total funding,. See insights on Invizius including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
INVIZIUS LIMITED Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for INVIZIUS LIMITED of EDINBURGH. Get the latest business insights from Dun & Bradstreet.See details»
Invizius - Overview, News & Similar companies | ZoomInfo.com
Invizius Treats First Patients in First-In-Human Phase 1 Clinical Study of Lead Dialysis Product H-Guard® First patients treated with H-Guard® at the National Institute for Health and Care …See details»
About Invizius - PharmiWeb.jobs
Feb 7, 2024 Invizius’ proprietary approach was born out of over ten years of research by Dr Andy Herbert into how pathogenic microbes evade the human complement system. Invizius is …See details»
About - Invizius - second generation complement therapeutics for ...
Invizius is the trading name of Invizius Limited. Invizius Limited is a limited company registered in Scotland, UK, with registration number SC586903. Invizius Limited's registered office is at …See details»
Invizius - F6S
Invizius is a spin-out based on world-class research carried out at the University of Edinburgh, Scotland, developing solutions to improve the treatment and prognosis for dialysis patients. …See details»
Invizius - Contacts, Employees, Board Members, Advisors & Alumni
Invizius provides dialysis treatments and other extra-corporeal treatments for patients.See details»
Invizius - MBM Commercial
Invizius spun-out of the University of Edinburgh in 2018 following research by the current CTO and co-founder Dr Andy Herbert. Over 3 million people in the UK live with chronic kidney …See details»
Home - Invizius - second generation complement therapeutics for ...
Invizius is a clinical stage biotech developing second generation complement therapies to treat inflammatory, fibrotic and autoimmune disorders Our Pipeline > Our proprietary technology …See details»
Invizius - CipherBio
Explore Invizius's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
News & Events - Invizius - second generation complement …
Read the Invizius's latest announcements here: News & Events - Invizius - second generation complement therapeutics for autoimmune and inflammatory disorders About UsSee details»
Invizius - Funding, Financials, Valuation & Investors - Crunchbase
Invizius provides dialysis treatments and other extra-corporeal treatments for patients. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. ... How much …See details»
Invizius Company Information - Funding, Investors, and More
The company Invizius has raised a total of $1.3m in funding over 1 rounds. Key Insights: Series A: $1.3m; 2024. Invizius Series A Round, September 2024 $1.3m. Similar startup. Track over …See details»
Meso-Guard™ for Peritoneal Dialysis - Invizius - second generation ...
At Invizius we are developing products to treat diseases driven by excessive activation of the patient's complement system. Our first product, H-Guard® Priming Solution, is initially …See details»
Our complement therapy platform is inspired by the ... - Invizius
Invizius’s technical co-founders researched one of its key mechanisms for hiding from the complement (or innate immune) system – the pneumococcal surface protein C (PspCN) – a …See details»